These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31530405)

  • 1. [An integral view of cancer (II). Fields of investigation and emerging biomarkers].
    Noguera R; Burgos-Panadero R; Gamero-Sandemetrio E; de la Cruz-Merino L; Álvaro Naranjo T
    Rev Esp Patol; 2019; 52(4):222-233. PubMed ID: 31530405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [An integral view of cancer (III). Evaluation of new biomarkers and treatment strategies].
    Noguera R; Burgos-Panadero R; Lucantoni F; de la Cruz-Merino L; Álvaro Naranjo T
    Rev Esp Patol; 2020; 53(2):88-99. PubMed ID: 32199599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An integral view of cancer (I). The study, classification and reprogramming of the tumoral microclimate].
    Noguera R; Burgos-Panadero R; Gamero-Sandemetrio E; de la Cruz-Merino L; Álvaro Naranjo T
    Rev Esp Patol; 2019; 52(2):92-102. PubMed ID: 30902384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic reprogramming: the emerging concept and associated therapeutic strategies.
    Yoshida GJ
    J Exp Clin Cancer Res; 2015 Oct; 34():111. PubMed ID: 26445347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Strategies around PD-L1 testing in France].
    Penault-Llorca F
    Ann Pathol; 2017 Feb; 37(1):3-4. PubMed ID: 28108043
    [No Abstract]   [Full Text] [Related]  

  • 7. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy.
    Rivadeneira DB; Delgoffe GM
    Clin Cancer Res; 2018 Jun; 24(11):2473-2481. PubMed ID: 29386217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
    Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
    J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?
    Zito Marino F; Ascierto PA; Rossi G; Staibano S; Montella M; Russo D; Alfano R; Morabito A; Botti G; Franco R
    Expert Opin Biol Ther; 2017 Jun; 17(6):735-746. PubMed ID: 28318336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy.
    Huang L; Xu H; Peng G
    Cell Mol Immunol; 2018 May; 15(5):428-437. PubMed ID: 29553135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment.
    Jiang Z; Liu Z; Li M; Chen C; Wang X
    EBioMedicine; 2019 Apr; 42():431-442. PubMed ID: 30935888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Which future for B lymphocytes infiltrating solid tumors: prognostic biomarker and/or therapeutic target?].
    Kaplon H; Dieu-Nosjean MC
    Med Sci (Paris); 2018 Jan; 34(1):72-78. PubMed ID: 29384099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
    Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ
    Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer.
    Anari F; Ramamurthy C; Zibelman M
    Future Oncol; 2018 Jun; 14(14):1409-1421. PubMed ID: 29848096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.
    Xie G; Cheng T; Lin J; Zhang L; Zheng J; Liu Y; Xie G; Wang B; Yuan Y
    J Immunother Cancer; 2018 Sep; 6(1):88. PubMed ID: 30208943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The gut microbiome and cancer immunotherapeutics: A review of emerging data and implications for future gynecologic cancer research.
    McKenzie ND; Hong H; Ahmad S; Holloway RW
    Crit Rev Oncol Hematol; 2021 Jan; 157():103165. PubMed ID: 33227575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma].
    Adam J; Tomasic G; Robert C
    Ann Pathol; 2017 Feb; 37(1):55-60. PubMed ID: 28111041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
    Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
    Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of immunotherapy for gastrointestinal stromal tumor.
    Tan Y; Trent JC; Wilky BA; Kerr DA; Rosenberg AE
    Cancer Gene Ther; 2017 Mar; 24(3):130-133. PubMed ID: 28186088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.